Neogenomics stock gets Medicare coverage for blood-based test By Investing.com

Neogenomics received Medicare coverage for its PanTracer LBx blood-based CGP test, reimbursed at approximately $3,288–$3,289 per test; TD Cowen reiterated a Buy with a $16 target and estimates coverage could lift 2026 revenue by ~3–4%. NeoGenomics beat Q4 2025 expectations with EPS $0.06 vs $0.04 and revenue $190.17M vs $188.14M; Needham raised its price target to $15 and Leerink maintained a $14 target/Market Perform. Shares trade at $8.20, well below analyst target range of $13–$17, and InvestingPro flags the stock as undervalued relative to fair value.

Analysis

Incremental payer coverage for a commercializable blood-based CGP test is not linear — it leverages heavy fixed-cost lab infrastructure so that modest volume growth can disproportionately flow to EBITDA. Expect the near-term P&L sensitivity to be concentrated in gross margin expansion and cash conversion rather than large top-line multiples; a 6–12 month window of rising utilization should show up first in utilization rates per sequencer, then in sequential margin improvement and working capital normalization.

Competitive dynamics are asymmetric. Public peers focused solely on plasma CGP face faster scale benefits but also greater exposure to single-test commoditization and reagent supply risk; vertically integrated labs with mixed tissue/blood portfolios can defend pricing through bundled offerings and payer contracting. Second-order winners include midsize oncology practices and CROs that increase clinical-trial referrals as liquid CGP lowers screening friction, while reagent OEMs may see lumpy demand requiring careful vendor management.

Key risks that would reverse the constructive path are payer re-pricing, MolDX/local-coverage reversals, or new negative comparative utility data — any of which can compress price per test or increase denial/appeal costs. Watch the next 3–9 months for payer denial rates, test volumes per sales rep, and any announced capacity investments; each is a high-information catalyst.

The market is split between underpricing durable commercial adoption and overvaluing immediate revenue run-rate recovery. Outperformance requires verifying operational traction (test conversion, ARPU, denial trends) rather than relying on headline policy wins alone.

Key Decisions for Investors

• Long NEO equity (size 1–2% NAV) with a 9–12 month horizon: thesis is margin/EBITDA leverage from utilization uptick. Risk: 25–30% stop-loss; target: 50–80% upside conditional on sequential margin improvement and sustained test volumes.
• Buy a 9–12 month call spread on NEO (debit-limited): buy near-term LEAP call and sell a higher strike ~50–70% above current to cap premium. Allocate 0.5–1% NAV; this preserves upside while limiting cash at risk to a small, defined amount.
• Pair trade: long NEO / short GH (dollar-neutral, 6–12 month): exploits potential relative rerating if NEO's commercial execution outpaces peers. Hedge size to 0.5–1% NAV each leg; risk if sector-wide re-rating lifts both names.
• Monitor triggers (weekly cadence): 1) tests/month growth rate, 2) payer denial/appeal trend, 3) gross margin per test, 4) announced capex for capacity. If two of four metrics miss expectations over a rolling 2-quarter period, reduce gross exposure by 50%.